Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer
Status:
Terminated
Trial end date:
2020-01-17
Target enrollment:
Participant gender:
Summary
The benefit of aspirin in cancer of the colon and rectum is already known. Recently, it was
described its potential activity during chemoradiotherapy, with higher rate of tumor
downstaging. Furthermore, induction chemotherapy followed by chemoradiation represents an
attractive approach, with more favorable compliance and toxicity profiles. The aim of this
study was to evaluate the efficacy of total neoadjuvant treatment and assess the efficacy and
feasibility of aspirin use during chemoradiotherapy for high-risk rectal cancer.